These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 33050407)

  • 1. Bullous Pemphigoid: Trigger and Predisposing Factors.
    Moro F; Fania L; Sinagra JLM; Salemme A; Di Zenzo G
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33050407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies.
    Lo Schiavo A; Ruocco E; Brancaccio G; Caccavale S; Ruocco V; Wolf R
    Clin Dermatol; 2013; 31(4):391-399. PubMed ID: 23806156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and presumptive triggers of localized bullous pemphigoid.
    Ständer S; Kasperkiewicz M; Thaçi D; Schmidt E; Zillikens D; Vorobyev A; Ludwig RJ
    J Dermatol; 2021 Aug; 48(8):1257-1261. PubMed ID: 33998059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bullous pemphigoid (BP) patients with selective IgG autoreactivity against BP230: Review of a rare but valuable cohort with impact on the comprehension of the pathogenesis of BP.
    Ramcke T; Vicari E; Bolduan V; Enk A; Hadaschik E
    J Dermatol Sci; 2022 Feb; 105(2):72-79. PubMed ID: 34930674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IgG antibodies against immunodominant C-terminal epitopes of BP230 do not induce skin blistering in mice.
    Feldrihan V; Licarete E; Florea F; Cristea V; Popescu O; Sitaru C; Chiriac MT
    Hum Immunol; 2014 Apr; 75(4):354-63. PubMed ID: 24468586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bullous pemphigoid: An immune disorder related to aging (Review).
    Deotto ML; Spiller A; Sernicola A; Alaibac M
    Exp Ther Med; 2022 Jan; 23(1):50. PubMed ID: 34934428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies to BPAG1e Trigger Experimental Bullous Pemphigoid in Mice.
    Makita E; Matsuzaki Y; Fukui T; Matsui A; Minakawa S; Nakano H; Ito K; Kijima H; Sawamura D
    J Invest Dermatol; 2021 May; 141(5):1167-1176.e3. PubMed ID: 33069726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Checkpoint Inhibition May Trigger the Rare Variant of Anti-LAD-1 IgG-Positive, Anti-BP180 NC16A IgG-Negative Bullous Pemphigoid.
    Sadik CD; Langan EA; Grätz V; Zillikens D; Terheyden P
    Front Immunol; 2019; 10():1934. PubMed ID: 31474998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-hit hypothesis of bullous pemphigoid and associated neurological disease: Is HLA-DQB1*03:01, a potential link between immune privileged antigen exposure and epitope spreading?
    Amber KT; Zikry J; Hertl M
    HLA; 2017 Mar; 89(3):127-134. PubMed ID: 28101965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the combination of BP180-NC16a enzyme-linked immunosorbent assay and BP230 enzyme-linked immunosorbent assay in the diagnosis of bullous pemphigoid.
    Yang B; Wang C; Chen S; Chen X; Lu X; Tian H; Yu M; Zhang D; Shi Z; Zhou G; Zhang F
    Indian J Dermatol Venereol Leprol; 2012; 78(6):722-7. PubMed ID: 23075641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical manifestations in 100 Japanese bullous pemphigoid cases in relation to autoantigen profiles.
    Tanaka M; Hashimoto T; Dykes PJ; Nishikawa T
    Clin Exp Dermatol; 1996 Jan; 21(1):23-7. PubMed ID: 8689764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eosinophils, Basophils, and Neutrophils in Bullous Pemphigoid.
    Limberg MM; Weihrauch T; Gray N; Ernst N; Hartmann K; Raap U
    Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bullous pemphigoid: clinical practice guidelines.
    Fuertes de Vega I; Iranzo-Fernández P; Mascaró-Galy JM
    Actas Dermosifiliogr; 2014 May; 105(4):328-46. PubMed ID: 23540594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of physical factors in the pathogenesis of bullous pemphigoid: Case report series and a comprehensive review of the published work.
    Dănescu S; Chiorean R; Macovei V; Sitaru C; Baican A
    J Dermatol; 2016 Feb; 43(2):134-40. PubMed ID: 26173987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Insights Into the Pathogenesis of Bullous Pemphigoid: 2019 Update.
    Genovese G; Di Zenzo G; Cozzani E; Berti E; Cugno M; Marzano AV
    Front Immunol; 2019; 10():1506. PubMed ID: 31312206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bullous pemphigoid].
    Schulze F; Kasperkiewicz M; Zillikens D; Schmidt E
    Hautarzt; 2013 Dec; 64(12):931-43; quiz 944-5. PubMed ID: 24337308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bullous pemphigoid.
    Miyamoto D; Santi CG; Aoki V; Maruta CW
    An Bras Dermatol; 2019; 94(2):133-146. PubMed ID: 31090818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics.
    Nishie W
    Immunol Med; 2019 Mar; 42(1):22-28. PubMed ID: 31169082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eosinophils as putative therapeutic targets in bullous pemphigoid.
    Simon D; Borradori L; Simon HU
    Exp Dermatol; 2017 Dec; 26(12):1187-1192. PubMed ID: 28833620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bullous Pemphigoid Triggered by Thermal Burn Under Medication With a Dipeptidyl Peptidase-IV Inhibitor: A Case Report and Review of the Literature.
    Mai Y; Nishie W; Sato K; Hotta M; Izumi K; Ito K; Hosokawa K; Shimizu H
    Front Immunol; 2018; 9():542. PubMed ID: 29706950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.